BTG pushes back Voraxaze BLA again
This article was originally published in Scrip
Executive Summary
BTG has once again delayed the rolling BLA for Voraxaze (glucarpidase) for another six months to provide ''a more robust BLA clinical package''. The drug is to be used to reduce levels of the cancer drug methotrexate in patients who have toxic levels of the agent due to impaired renal function.